|
1
|
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and
Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev
Clin Oncol. 10:643–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Masoudi-Nejad A and Asgari Y: Metabolic
cancer biology: Structural-based analysis of cancer as a metabolic
disease, new sights and opportunities for disease treatment. Semin
Cancer Biol. 30:21–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pavlova NN and Thompson CB: The emerging
hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shen CT, Wei WJ, Qiu ZL, Song HJ and Luo
QY: Afamin promotes glucose metabolism in papillary thyroid
carcinoma. Mol Cell Endocrinol. 434:108–115. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jan CI, Tsai MH, Chiu CF, Huang YP, Liu CJ
and Chang NW: Fenofibrate suppresses oral tumorigenesis via
reprogramming metabolic processes: Potential drug repurposing for
oral cancer. Int J Biol Sci. 12:786–798. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Navarro P, Bueno MJ, Zagorac I, Mondejar
T, Sanchez J, Mourón S, Muñoz J, Gómez-López G, Jimenez-Renard V,
Mulero F, et al: Targeting tumor mitochondrial metabolism overcomes
resistance to antiangiogenics. Cell Rep. 15:2705–2718. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Z, Yang P and Li Z: The multifaceted
regulation and functions of PKM2 in tumor progression. Biochim
Biophys Acta. 1846:285–296. 2014.PubMed/NCBI
|
|
9
|
Jurica MS, Mesecar A, Heath PJ, Shi W,
Nowak T and Stoddard BL: The allosteric regulation of pyruvate
kinase by fructose-1,6-bisphosphate. Structure. 6:195–210. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tamada M, Suematsu M and Saya H: Pyruvate
kinase M2: Multiple faces for conferring benefits on cancer cells.
Clin Cancer Res. 18:5554–5561. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Christofk HR, Vander Heiden MG, Harris MH,
Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and
Cantley LC: The M2 splice isoform of pyruvate kinase is important
for cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Christofk HR, Vander Heiden MG, Wu N,
Asara JM and Cantley LC: Pyruvate kinase M2 is a
phosphotyrosine-binding protein. Nature. 452:181–186. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu WR, Tian MX, Yang LX, Lin YL, Jin L,
Ding ZB, Shen YH, Peng YF, Gao DM, Zhou J, et al: PKM2 promotes
metastasis by recruiting myeloid-derived suppressor cells and
indicates poor prognosis for hepatocellular carcinoma. Oncotarget.
6:846–861. 2015.PubMed/NCBI
|
|
14
|
Mukherjee J, Ohba S, See WL, Phillips JJ,
Molinaro AM and Pieper RO: PKM2 uses control of HuR localization to
regulate p27 and cell cycle progression in human glioblastoma
cells. Int J Cancer. 139:99–111. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong N, Yan J, Ojo D, De Melo J, Cutz JC
and Tang D: Changes in PKM2 associate with prostate cancer
progression. Cancer Invest. 32:330–338. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shashni B, Sakharkar KR, Nagasaki Y and
Sakharkar MK: Glycolytic enzymes PGK1 and PKM2 as novel
transcriptional targets of PPARγ in breast cancer pathophysiology.
J Drug Target. 21:161–174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu G, Yu W, Jin G, Xu D, Chen Y, Xia T, Yu
A, Fang W, Zhang X, Li Z and Xie K: PKM2 regulates neural invasion
of and predicts poor prognosis for human hilar cholangiocarcinoma.
Mol Cancer. 14:1932015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen G, Feng W, Zhang S, Bian K, Yang Y,
Fang C, Chen M, Yang J and Zou X: Metformin inhibits gastric cancer
via the inhibition of HIF1α/PKM2 signaling. Am J Cancer Res.
5:1423–1434. 2015.PubMed/NCBI
|
|
19
|
Gao Y, Xu D, Yu G and Liang J:
Overexpression of metabolic markers HK1 and PKM2 contributes to
lymphatic metastasis and adverse prognosis in Chinese gastric
cancer. Int J Clin Exp Pathol. 8:9264–9271. 2015.PubMed/NCBI
|
|
20
|
Tang R, Yang C, Ma X, Wang Y, Luo D, Huang
C, Xu Z, Liu P and Yang L: MiR-let-7a inhibits cell proliferation,
migration, and invasion by down-regulating PKM2 in gastric cancer.
Oncotarget. 7:5972–5984. 2016.PubMed/NCBI
|
|
21
|
Luo W and Semenza GL: Emerging roles of
PKM2 in cell metabolism and cancer progression. Trends Endocrinol
Metab. 23:560–566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Panasyuk G, Espeillac C, Chauvin C,
Pradelli LA, Horie Y, Suzuki A, Annicotte JS, Fajas L, Foretz M,
Verdeguer F, et al: PPARγ contributes to PKM2 and HK2 expression in
fatty liver. Nat Commun. 3:6722012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen L, Shi Y, Liu S, Cao Y, Wang X and
Tao Y: PKM2: The thread linking energy metabolism reprogramming
with epigenetics in cancer. Int J Mol Sci. 15:11435–11445. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shuch B, Linehan WM and Srinivasan R:
Aerobic glycolysis: A novel target in kidney cancer. Expert Rev
Anticancer Ther. 13:711–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun Q, Chen X, Ma J, Peng H, Wang F, Zha
X, Wang Y, Jing Y, Yang H, Chen R, et al: Mammalian target of
rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is
critical for aerobic glycolysis and tumor growth. Proc Natl Acad
Sci USA. 108:pp. 4129–4134. 2011; View Article : Google Scholar : PubMed/NCBI
|
|
26
|
García-Carracedo D, Villaronga MÁ,
Álvarez-Teijeiro S, Hermida-Prado F, Santamaría I, Allonca E,
Suárez-Fernández L, Gonzalez MV, Balbín M, Astudillo A, et al:
Impact of PI3K/AKT/mTOR pathway activation on the prognosis of
patients with head and neck squamous cell carcinomas. Oncotarget.
7:29780–29793. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen S, Fisher RC, Signs S, Molina LA,
Shenoy AK, Lopez MC, Baker HV, Koomen JM, Chen Y, Gittleman H, et
al: Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing
colon cancer stem cells reduces tumor growth due to apoptosis.
Oncotarget. 8:50476–50488. 2016.PubMed/NCBI
|
|
28
|
Petrov A, Beer M and Blome S: Development
and validation of a harmonized TaqMan-based triplex real-time
RT-PCR protocol for the quantitative detection of normalized gene
expression profiles of seven porcine cytokines. PLoS One.
9:e1089102014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bauer TM, Patel MR and Infante JR:
Targeting P13Kinase in cancer. Pharmacol Ther. 146:53–60. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ying J, Xu Q, Liu B, Zhang G, Chen L and
Pan H: The expression of the PI3K/AKT/mTOR pathway in gastric
cancer and its role in gastric cancer prognosis. Onco Targets Ther.
8:2427–2433. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu L, Derijard B, Chakrabandhu K, Wang
BS, Chen HZ and Hueber AO: Synergism of PI3K/Akt inhibition and Fas
activation on colon cancer cell death. Cancer Lett. 354:355–364.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Denoyelle C, Lambert B, Meryet-Figuière M,
Vigneron N, Brotin E, Lecerf C, Abeilard E, Giffard F, Louis MH,
Gauduchon P, et al: miR-491-5p-induced apoptosis in ovarian
carcinoma depends on the direct inhibition of both BCL-XL and EGFR
leading to BIM activation. Cell Death Dis. 5:e14452014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Houédé N and Pourquier P: Targeting the
genetic alterations of the PI3K-AKT-mTOR pathway: Its potential use
in the treatment of bladder cancers. Pharmacol Ther. 145:1–18.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang L, Wu J, Lu J, Ma R, Sun D and Tang
J: Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway
by tanshinone I in human breast cancer cell lines. Mol Med Rep.
11:931–939. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li Y, Zhang Z, Zhang X, Lin Y, Luo T, Xiao
Z and Zhou Q: A dual PI3K/AKT/mTOR signaling inhibitor miR-99a
suppresses endometrial carcinoma. Am J Transl Res. 8:719–731.
2016.PubMed/NCBI
|
|
37
|
Su CC and Chiu TL: Tanshinone IIA
decreases the protein expression of EGFR and IGFR blocking the
PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro
and in vivo. Oncol Rep. 36:1173–1179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Riquelme I, Tapia O, Espinoza JA, Leal P,
Buchegger K, Sandoval A, Bizama C, Araya JC, Peek RM and Roa JC:
The gene expression status of the PI3K/AKT/mTOR pathway in gastric
cancer tissues and cell lines. Pathol Oncol Res. 22:797–805. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu L, Chen X, Wang L and Chen S: The sweet
trap in tumors: Aerobic glycolysis and potential targets for
therapy. Oncotarget. 7:38908–38926. 2016.PubMed/NCBI
|
|
40
|
Chu B, Wang J, Wang Y and Yang G:
Knockdown of PKM2 induces apoptosis and autophagy in human A549
alveolar adenocarcinoma cells. Mol Med Rep. 12:4358–4363. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun H, Zhu A, Zhang L, Zhang J, Zhong Z
and Wang F: Knockdown of PKM2 suppresses tumor growth and invasion
in lung adenocarcinoma. Int J Mol Sci. 16:24574–24587. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
He Y, Wang Y, Liu H, Xu X, He S, Tang J,
Huang Y, Miao X, Wu Y, Wang Q and Cheng C: Pyruvate kinase isoform
M2 (PKM2). participates in multiple myeloma cell proliferation,
adhesion and chemoresistance. Leuk Res. 39:1428–1436. 2015.
|
|
43
|
Liu Q, Liang M, Liu T, Vuitton L, Zheng S,
Gao X, Lu M, Li X, Sheyhidin I and Lu X: M2 isoform of pyruvate
kinase (PKM2) is upregulated in Kazakh's ESCC and promotes
proliferation and migration of ESCC cells. Tumour Biol.
37:2665–2672. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mohammad GH, Olde Damink SW, Malago M,
Dhar DK and Pereira SP: Pyruvate kinase M2 and lactate
dehydrogenase a are overexpressed in pancreatic cancer and
correlate with poor outcome. PLoS One. 11:e01516352016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lu W, Cao Y, Zhang Y, Li S, Gao J, Wang
XA, Mu J, Hu YP, Jiang L, Dong P, et al: Up-regulation of PKM2
promote malignancy and related to adverse prognostic risk factor in
human gallbladder cancer. Sci Rep. 6:263512016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nemazanyy I, Espeillac C, Pende M and
Panasyuk G: Role of PI3K, mTOR and Akt2 signalling in hepatic
tumorigenesis via the control of PKM2 expression. Biochem Soc
Trans. 41:917–922. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang L, Hou Y, Yuan J, Tang S, Zhang H,
Zhu Q, Du YE, Zhou M, Wen S, Xu L, et al: Twist promotes
reprogramming of glucose metabolism in breast cancer cells through
PI3K/AKT and p53 signaling pathways. Oncotarget. 6:25755–25769.
2015.PubMed/NCBI
|
